EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Trends in immune activation, maturation, and co-stimulatory markers in a group of children with stable HIV infection before and after HAART Preliminary analysis of the PACTG 377 protocol



Trends in immune activation, maturation, and co-stimulatory markers in a group of children with stable HIV infection before and after HAART Preliminary analysis of the PACTG 377 protocol



Journal of Allergy & Clinical Immunology 109(1 Supplement): S199, January




(PDF same-day service: $19.90)

Accession: 035985375

Download citation: RISBibTeXText

DOI: 10.1016/s0091-6749(02)81730-4



Related references

Highly active antiretroviral therapy (HAART) and circulating markers of immune activation: specific effect of HAART on neopterin. Clinical and Diagnostic Laboratory Immunology 7(5): 832-834, 2000

Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225. Journal of Infectious Diseases 204 Suppl 1(): S179-S189, 2011

Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. Aids Research and Human Retroviruses 22(3): 213-221, 2006

T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: A longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 95(1): 249-255, 2000

T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 95(1): 249-255, 1999

The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. Aids 29(4): 463-471, 2015

Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team. Aids Research and Human Retroviruses 16(12): 1113-1121, 2000

Naive and memory CD4+ T cells and T cell activation markers in HIV-1 infected children on HAART. Clinical & Experimental Immunology 125(2): 266-273, August, 2001

Preliminary evaluation of nelfinavir pharmacodynamics in stable antiretroviral experienced HIV-infected children following initiation of HAART. Pediatric Research 45(4 PART 2): 164A, April, 1999

Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clinical Trials 9(2): 115-125, 2008

Elevated serum levels of soluble immune activation markers are associated with increased risk for death in HAART-naive HIV-1-infected patients. Aids Patient Care and Stds 17(4): 147-153, 2003

Analysis of residual HIV-1 replication, proviral HIV-1 DNA and immune activation in patients on HAART. Infection 29(Supplement 1): 9-10, 2001

Changes in cellular immune activation and memory T-cell subsets in HIV-infected Zambian children receiving HAART. Journal of Acquired Immune Deficiency Syndromes 67(5): 455-462, 2015

Immune recovery following antineoplastic chemotherapy and highly active antiretroviral therapy (HAART) in a child with HIV-1 infection previously unresponsive to HAART. International Journal of Immunopathology and Pharmacology 19(4): 919-922, 2006